Aureus Asset Management LLC Has $34.63 Million Holdings in HealthEquity, Inc. (NASDAQ:HQY)

Aureus Asset Management LLC lowered its stake in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 5.1% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 423,082 shares of the company's stock after selling 22,909 shares during the quarter. HealthEquity makes up about 2.3% of Aureus Asset Management LLC's holdings, making the stock its 19th biggest position. Aureus Asset Management LLC owned about 0.48% of HealthEquity worth $34,629,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Wasatch Advisors LP lifted its stake in shares of HealthEquity by 6.6% during the third quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company's stock valued at $635,065,000 after buying an additional 483,269 shares during the period. Clearbridge Investments LLC lifted its stake in shares of HealthEquity by 1.9% during the 2nd quarter. Clearbridge Investments LLC now owns 2,377,204 shares of the company's stock worth $204,915,000 after purchasing an additional 43,491 shares during the period. Mackenzie Financial Corp boosted its holdings in shares of HealthEquity by 16.0% during the second quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company's stock worth $203,822,000 after purchasing an additional 325,906 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of HealthEquity by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,547,402 shares of the company's stock valued at $133,377,000 after purchasing an additional 115,841 shares during the period. Finally, Loomis Sayles & Co. L P increased its stake in HealthEquity by 2.2% in the third quarter. Loomis Sayles & Co. L P now owns 1,126,645 shares of the company's stock valued at $92,216,000 after purchasing an additional 24,665 shares during the last quarter. Institutional investors and hedge funds own 99.55% of the company's stock.

Insider Transactions at HealthEquity

In other HealthEquity news, Director Robert W. Selander sold 8,250 shares of the stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total transaction of $684,585.00. Following the completion of the transaction, the director now directly owns 54,719 shares of the company's stock, valued at approximately $4,540,582.62. This trade represents a 13.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Frank Corvino sold 1,039 shares of HealthEquity stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total value of $99,847.90. Following the transaction, the director now directly owns 3,784 shares in the company, valued at approximately $363,642.40. The trade was a 21.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,536 shares of company stock worth $884,517. Company insiders own 2.20% of the company's stock.

Wall Street Analysts Forecast Growth

HQY has been the topic of a number of recent analyst reports. The Goldman Sachs Group started coverage on shares of HealthEquity in a research note on Friday, November 15th. They set a "neutral" rating and a $108.00 price target on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $105.00 price target on shares of HealthEquity in a research note on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft boosted their price target on HealthEquity from $102.00 to $103.00 and gave the stock a "buy" rating in a research note on Wednesday, September 4th. BTIG Research lifted their price objective on HealthEquity from $110.00 to $130.00 and gave the stock a "buy" rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $92.00 target price on shares of HealthEquity in a research note on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $108.38.

HealthEquity Stock Performance

Shares of NASDAQ HQY traded up $0.12 during mid-day trading on Monday, hitting $101.66. The company had a trading volume of 574,970 shares, compared to its average volume of 624,470. HealthEquity, Inc. has a 12 month low of $62.10 and a 12 month high of $105.82. The stock has a market cap of $8.88 billion, a price-to-earnings ratio of 84.62, a PEG ratio of 1.59 and a beta of 0.52. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.10 and a quick ratio of 4.10. The firm's 50 day simple moving average is $90.16 and its two-hundred day simple moving average is $82.85.

HealthEquity (NASDAQ:HQY - Get Free Report) last posted its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.50 by $0.16. The company had revenue of $299.93 million for the quarter, compared to analysts' expectations of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. As a group, equities research analysts forecast that HealthEquity, Inc. will post 2.27 earnings per share for the current year.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.